All Stories

  1. Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP)
  2. Aldosterone Synthase Inhibitors for Resistant Hypertension: Pharmacological Insights – A Systematic Review
  3. Evaluating the Prognostic Significance of Circulating Biomarkers of End Organ Damage in Hypertension
  4. A 360° Perspective on Cardiovascular Prevention: the International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE)
  5. Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention
  6. Correction to “Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015)” [The Lancet Regional Health – Europe 49 (2025) 101182]
  7. Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis
  8. Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015)
  9. Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine
  10. Coffee, Anxiety, and Depression
  11. Abstract 4136758: Apabetalone: evaluating cardiovascular and safety outcomes in meta-analysis
  12. Reaping the rewards of a simplified dosing regimen
  13. 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)
  14. The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.
  15. Advancements in curcumin-loaded PLGA nanoparticle delivery systems: progressive strategies in cancer therapy
  16. Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS) - study design and methodology.
  17. 2024 Update on Postmarketing Nutrivigilance Safety Profile: A Line of Dietary Food Supplements Containing Red Yeast Rice for Dyslipidemia.
  18. Patient experiences of their current asthma care and their views toward providing support for patients with asthma in community pharmacy: A Qualitative study
  19. 163 Prediction of outcomes in patients with hypertension using clinical laboratory biomarkers - a real-world analysis using a global federated database
  20. Could siRNA therapeutics change the way we treat dyslipidemia?
  21. Using read-across to build physiologically-based kinetic models: Part 1. Development of a KNIME workflow to assist analogue selection for PBK modelling
  22. Using Read-Across to build Physiologically-Based Kinetic models: Part 2. Case studies for atenolol and flumioxazin
  23. 4CPS-075 A systematic review of the target pharmacokinetic/pharmacodynamic parameters of antibiotics treating gram-negative infections
  24. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial
  25. Adherence to the Atrial fibrillation Better Care pathway and the risk of adverse health outcomes in older care home residents with atrial fibrillation: a retrospective data linkage study 2003–18
  26. Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF) using sensors embedded in the handles of supermarket trolleys: A feasibility study.
  27. Pharmacist-led intervention for older people with atrial fibrillation in long-term care (PIVOTALL study): a randomised pilot and feasibility study
  28. Managing older people with atrial fibrillation and preventing stroke: a review of anticoagulation approaches
  29. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants
  30. S12 | Finding synergies for 3Rs – toxicokinetics, physiologically-based kinetic (PBK) models and read-across
  31. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis
  32. Therapeutic drug monitoring: applying the ‘Goldilocks Principle’ to clinical pharmacology
  33. The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper.
  34. Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies
  35. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  36. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
  37. Which Statin is Best for the Kidneys?
  38. Statin Intolerance: An Overview for Clinicians
  39. Do antihypertensive medicines increase the risk of depression?
  40. 1208 FEASIBILITY OF A PHARMACIST-LED INTERVENTION FOR ATRIAL FIBRILLATION IN LONG-TERM CARE: THE PIVOTALL STUDY
  41. Abstracts of the 18th Congress of the European Geriatric Medicine Society
  42. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  43. Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
  44. Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study
  45. 2022: The Year in Cardiovascular Disease – The Year of Upfront Lipid Lowering Combination Therapy.
  46. Adherence to statin therapy - it seems we know everything, yet we do nothing…
  47. Individualized therapy in statin intolerance: the key to success
  48. Factors associated with prescription of oral anticoagulation for atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  49. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  50. Selected Abstracts from Pharmacology 2022
  51. Risk factors for post sternotomy wound complications across the patient journey: A systematised review of the literature
  52. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel
  53. P17-04 An automated tool for selection of chemical analogues to facilitate development of new physiologically-based kinetic models using a read-across approach
  54. Integrated care for atrial fibrillation management: The role of the pharmacist
  55. 1300 Transfer of outpatient paediatric prescriptions to primary care via the Electronic Prescription Service (EPS)- community pharmacist views
  56. Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review
  57. Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
  58. Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol
  59. Lifetime serum concentration of 25-hydroxyvitamin D 25(OH) is associated with hand grip strengths: insight from a Mendelian randomisation
  60. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
  61. Prevalence of statin intolerance: a meta-analysis
  62. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition
  63. Warfarin—Is Self-Care the Best Care?
  64. Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress
  65. Stop and Go: Barriers and Facilitators to Care Home Research
  66. Long-COVID-19: Definition, Epidemiology, and Clinical Implications
  67. CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities
  68. Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm
  69. The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study
  70. A Systematic Review of Published Physiologically based Kinetic Models and an Assessment of their Chemical Space Coverage
  71. Extreme cardiovascular risk—do we need a new risk category?
  72. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study
  73. The management of asthma in adult patients in the community pharmacy setting: Literature review
  74. Associations between serum triglycerides and abdominal aortic calcification in a cross-sectional study from the United States of America
  75. Association between ankle-brachial index and cardiovascular mortality in a cohort from the United States of America
  76. The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients
  77. Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study
  78. Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland
  79. Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective
  80. Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials
  81. RNA Silencing in the Management of Dyslipidemias
  82. Bacterial lipopolysaccharide–Stoking the fire of residual risk?
  83. Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
  84. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis
  85. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
  86. Statins as anti-pyroptotic agents
  87. Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia
  88. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors - analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.
  89. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
  90. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)
  91. Assessment of asthma management in adult patients: A retrospective case-note review in a general practice
  92. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
  93. Exploring pharmacists’ views surrounding conscientious objection to abortion and implications in practice
  94. Prevalence of anti-nuclear autoantibodies (ANA) in the general Polish population - analysis of the influence of sex and age on the variability of ANA.
  95. Effects of statins on myocarditis: A review of underlying molecular mechanisms
  96. OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
  97. Drucebo effect – the challenge we should all definitely face!
  98. Lipid-lowering therapies: Better together
  99. OUP accepted manuscript
  100. Recent advancements in liposome-based strategies for effective drug delivery to the brain
  101. Management of Statin Intolerance
  102. Statins, COVID-19, and coronary artery disease: killing two birds with one stone
  103. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors
  104. Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go
  105. Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes
  106. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America
  107. LDL-C: lower is better for longer—even at low risk
  108. Pharmacist implementation of a treatment pathway for atrial fibrillation in care home residents
  109. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
  110. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
  111. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  112. Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?
  113. Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice
  114. What's new in lipid‐lowering pharmacology? Integrating basic and clinical research to improve patient outcomes
  115. Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)
  116. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
  117. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
  118. Liposome Circulation Time is Prolonged by CD47 Coating
  119. Intake of Caffeine and Its Association with Physical and Mental Health Status among University Students in Bahrain
  120. Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants
  121. Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection
  122. Vitamin D and SAMS
  123. Inclisiran—New hope in the management of lipid disorders?
  124. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications
  125. Statins and Lp(a): do not make perfect the enemy of excellent
  126. The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis
  127. P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel
  128. Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management
  129. A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome
  130. Regulatory T cells: possible mediators for the anti-inflammatory action of statins
  131. Genetic testing in familial hypercholesterolaemia: What does it add?
  132. Poster Abstracts
  133. Worldwide Dyslipidemia Guidelines
  134. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
  135. Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study
  136. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis
  137. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
  138. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
  139. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  140. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study
  141. P3836The prognostic accuracy of bleeding risk prediction scores in patients with atrial fibrillation: a systematic review and meta-analysis
  142. P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  143. Lipoprotein(a) and the risk of atrial fibrillation – is there a link
  144. The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis
  145. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
  146. Autonomic and Autacoid Pharmacology: Goodbye and thank you
  147. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
  148. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials
  149. 3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis
  150. 3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study
  151. P627Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study
  152. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis
  153. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
  154. 220 Daphnia magna as a model for quantifying chaos in cardiac arrhythmia
  155. Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease
  156. The role of nutraceuticals in the prevention of cardiovascular disease
  157. Evaluating bempedoic acid for the treatment of hyperlipidaemia
  158. Association between telomere length and complete blood count in US adults
  159. D-003 (Saccharum officinarum): The forgotten lipid-lowering agent
  160. Effects of pentoxifylline on inflammatory markers and blood pressure
  161. Sunday 28 August 2016
  162. Monday 29 August 2016
  163. Tuesday 30 August 2016
  164. Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?
  165. Autonomic & Autacoid Pharmacology 2016: The year in review
  166. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions
  167. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials
  168. Autonomic & Autacoid Pharmacology: past, present and future
  169. Developing skills to deliver alcohol screening and brief intervention (SBI) in community pharmacy
  170. Lecturing: A lost art
  171. ChemInform Abstract: Synthesis of Antagonists of Muscarinic (M3) Receptors.
  172. Synthesis of antagonists of muscarinic (M3) receptors
  173. Incense – A problematic method of drug-delivery
  174. Activation of β-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction
  175. Protective role of β2- and β3-adrenoceptors at reperfusion in isolated rat heart
  176. Vasopressors for cardiopulmonary resuscitation
  177. Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological properties
  178. The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia